EXPERIMENTAL ESTIMATION OF CORRECTION OF HUMORAL IMMUNITY HEPATOPROTECTIVE DRUG HEPATOBIOL IN LABORATORY ANIMALS C ACUTE TOXIC HEPATITIS

The article is devoted to topical issues of preclinical study developed a combined experimental sample of a hepatoprotective drug heptobiol on humoral immunity in laboratory animals and reproduced with a model of acute toxic liver damage. Results showed that the manifestation of the inflammatory syndrome was more pronounced in the group of experimental animals without treatment is reproduced with toxic hepatitis. In group I, in which laboratory animals were assigned to drug heptobiol, the pathological process were less pronounced than in group II received the reference drug ursosan. It should be noted that at the end of the observation period (30th day), group I noted the normalization of all studied parameters, in contrast to group II, in which indicators of inflammatory syndrome were not recovered.

гепатопротекторный препарат, гепатобиол, иммунотропное действие, иммуновоспалительные синдром, probiotic, the combined drug, hepatobiol, immunotropic effect, immune inflammatory syndrome